CLINICAL TRIALS PROFILE FOR TINIDAZOLE

All Clinical Trials for TINIDAZOLE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003617 ↗	Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach	Unknown status	Lymphoma Trials Office	Phase 3	1995-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known whether chlorambucil is more effective than observation in treating low-grade lymphoma of the stomach. PURPOSE: Randomized phase III trial to compare the effectiveness of chlorambucil with that of no further therapy following anti-Helicobacter therapy in treating patients with low-grade lymphoma of the stomach.
NCT00132171 ↗	Helicobacter Pylori Eradication With a New Sequential Treatment	Completed	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Phase 3	2001-01-01	Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. The study aimed to assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection.
NCT00132171 ↗	Helicobacter Pylori Eradication With a New Sequential Treatment	Completed	St. Orsola Hospital	Phase 3	2001-01-01	Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. The study aimed to assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection.
NCT00229216 ↗	Treatment of Bacterial Vaginosis With Oral Tinidazole	Completed	Mission Pharmacal	Phase 3	2005-01-01	The purpose of this study is to confirm the safety and efficacy of oral tinidazole for the treatment of bacterial vaginosis.
NCT00313131 ↗	Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments	Completed	Canadian International Development Agency	Phase 3	2004-01-01	This randomised controlled trial aimed to verify whether directly observed single dose treatment (with tinidazole+fluconazole) would be as effective as the longer standard treatments (metronidazole for 7 days, plus vaginal clotrimazole for 3 days) in the syndromic management of women presenting with vaginal discharge in primary health care centers of Ghana, Togo, Guinea and Mali. It was designed as an effectiveness trial, i.e. it was done under conditions typical of routine work in these health centers
NCT00313131 ↗	Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments	Completed	Université de Sherbrooke	Phase 3	2004-01-01	This randomised controlled trial aimed to verify whether directly observed single dose treatment (with tinidazole+fluconazole) would be as effective as the longer standard treatments (metronidazole for 7 days, plus vaginal clotrimazole for 3 days) in the syndromic management of women presenting with vaginal discharge in primary health care centers of Ghana, Togo, Guinea and Mali. It was designed as an effectiveness trial, i.e. it was done under conditions typical of routine work in these health centers
NCT00322465 ↗	NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2006-11-01	This study will look at the safety, effectiveness, and tolerability of combination medications for the initial treatment of non-gonococcal urethritis (NGU). NGU is inflammation of the tube that carries urine from the bladder. NGU is caused by bacteria that may be passed from person to person during sex. This study will compare the 2 currently recommended NGU treatments, doxycycline and azithromycin, taken with tinidazole (another medication to treat certain sexually transmitted infections). Tinidazole used with doxycycline or azithromycin may cure NGU better than when doxycycline or azithromycin is used alone. Study participants will be 300 men ages 16-45 years with NGU attending sexually transmitted disease clinics in Birmingham, AL; New Orleans, LA; Durham, NC; and Baltimore, MD. Study participation will last 7 weeks and involve 3 visits. At each visit, participants will provide a urine sample, have 2 urethral swabs, and have their urethra checked for discharge indicating infection.

Clinical Trial Conditions for TINIDAZOLE

Condition Name

Condition Name for TINIDAZOLE
Intervention	Trials
Helicobacter Pylori Infection	14
Bacterial Vaginosis	6
Helicobacter Infections	2
H. Pylori Infection	2

Condition MeSH

Condition MeSH for TINIDAZOLE
Intervention	Trials
Infections	12
Helicobacter Infections	11
Infection	8
Vaginosis, Bacterial	7

Clinical Trial Locations for TINIDAZOLE

Trials by Country

Trials by Country for TINIDAZOLE
Location	Trials
United States	11
Taiwan	7
China	6
Syrian Arab Republic	2
United Kingdom	2

Trials by US State

Trials by US State for TINIDAZOLE
Location	Trials
Texas	2
Alabama	2
North Carolina	2
Washington	1
Pennsylvania	1

Clinical Trial Progress for TINIDAZOLE

Clinical Trial Phase

Clinical Trial Phase for TINIDAZOLE
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	20
Phase 3	8

Clinical Trial Status

Clinical Trial Status for TINIDAZOLE
Clinical Trial Phase	Trials
Completed	24
Unknown status	7
Recruiting	6

Clinical Trial Sponsors for TINIDAZOLE

Sponsor Name

Sponsor Name for TINIDAZOLE
Sponsor	Trials
Mackay Memorial Hospital	4
Exeltis Turkey	2
National Institute of Allergy and Infectious Diseases (NIAID)	2

Sponsor Type

Sponsor Type for TINIDAZOLE
Sponsor	Trials
Other	45
Industry	8
NIH	2

Tinidazole Clinical Trials Update and Market Projection (2026–2035)

Last updated: April 23, 2026

Tinidazole is an established antiprotozoal and antibacterial agent with global generic availability and no current foothold of a new, proprietary pipeline that would materially change commercial expectations versus historical pricing and volume dynamics. Market behavior is governed primarily by (1) generic penetration, (2) periodic guideline-driven demand for specific indications, and (3) procurement and reimbursement cycles in institutional settings.

What is tinidazole and what is the clinical trial landscape?

Indication set that drives prescribing volume

Tinidazole is used across bacterial vaginosis and protozoal infections. In practice, demand clusters around:

• Bacterial vaginosis (women’s health, intermittent but recurring).
• Amoebiasis and giardiasis (infectious disease, higher episodic volume).
• Trichomoniasis (urology/gynecology; treatment protocols vary by region).
• Anaerobic bacterial infections in certain perioperative or mixed infections contexts (usage depends on local formulary and antibiotic pathways).

Tinidazole’s use patterns are typically less “pipeline-reactive” than newer antibiotic classes because clinicians often default to guideline-consistent, well-tolerated regimens using established agents.

Clinical trials update: status is “maintenance-level,” not disruptive

Across the last several years, the visible clinical trial activity for tinidazole has largely been in the form of:

• Bioequivalence (BE) studies for generic products.
• Adjunctive or comparative studies in established indications.
• Formulation/route work rather than novel mechanism-of-action development.

No material evidence indicates that tinidazole has entered a late-stage, mechanism-changing development cycle that would reprice the market globally in the near term. The trial footprint is dominated by generic support rather than new clinical endpoints that would expand indication scope or materially change safety/efficacy perceptions.

Evidence base: safety and efficacy are established

Tinidazole’s pharmacology and clinical use are well documented in regulatory labeling and standard references. Key points from product monographs include:

• Mechanism: nitroimidazole with activity against anaerobic bacteria and protozoa.
• Clinical positioning: used for specific protozoal infections and anaerobic bacterial infections; dosing regimens vary by indication.

Regulatory and reference sources anchor the current use pattern rather than new development.

How does the current market structure look?

Market structure: generic-led with price pressure

Tinidazole is widely off-patent and available in multiple forms globally (tablets, and in some markets formulations that support local substitution). This market structure implies:

• Price compression driven by generic competition.
• Tender-led uptake for institutional demand.
• Switching behavior at the pharmacy level driven by cost, availability, and formulary preference.

Competitive landscape

Competition comes from:

• Other nitroimidazoles (metronidazole; in some regions tinidazole vs metronidazole differentiation is based on tolerance, dosing convenience, and payer preference).
• Generic tinidazole brands in the same indication space.
• Local protocol alternatives (single-dose or multi-dose regimens that can displace tinidazole in certain settings).

Because tinidazole is an established drug with multiple equivalents, new entrants typically target distribution reach and unit economics rather than differentiated clinical value.

What do regulatory and labeling signals imply for near-term uptake?

Labeling and guideline consistency

Tinidazole labels and clinical references support use in standard indications (notably anaerobic infections and protozoal diseases). This is consistent with ongoing prescribing.

Substitution and therapeutic interchange

Where formularies list multiple nitroimidazoles, substitution tends to be cost- and access-driven:

• Hospitals and government buyers often select based on procurement price and supply reliability.
• Clinics may select based on regimen convenience and patient adherence needs.

These dynamics tend to stabilize volume but suppress price.

How big is the market and what is the projection logic?

Market projection framework (what determines the forecast)

A workable projection for an established generic drug uses three levers:

1. Unit demand stability from ongoing infection incidence and guideline adherence.
2. Share shifts within nitroimidazoles based on price and availability.
3. Real price erosion from generic competition, offset partly by volume growth in emerging markets.

Tinidazole sits in a mature category with:

• Limited scope for label expansion-led growth.
• High substitution risk.
• Predictable seasonal and incidence-driven demand patterns for infectious diseases.

Base-case outlook (2026–2035)

The projection profile for tinidazole is typically:

• Moderate volume growth in regions with expanding access and public-health coverage.
• Flat-to-declining pricing in markets with multiple suppliers.
• Revenue growth lagging volume in currency terms due to price erosion.

This yields a forecast pattern where market value grows slowly relative to underlying unit usage.

Segment-level expectations

• Women’s health (bacterial vaginosis): steady baseline; incremental growth follows population access rather than clinical breakthroughs.
• GI protozoal infections (amoebiasis, giardiasis): tied to regional incidence and treatment-seeking rates.
• Trichomoniasis: protocol adherence and public health programs influence uptake.
• Anaerobic infections: demand depends on hospital antibiotic pathways and formulary preference.

What are the biggest risks to the projection?

1. Continued price compression from additional generic entrants and tender re-tendering.
2. Formulary displacement by metronidazole or other alternatives where payers prioritize lower-cost equivalents.
3. Shifts in treatment guidelines that change preferred regimens or duration.
4. Supply chain disruptions affecting tender competitiveness and availability.

What are the actionable business implications for R&D and investment?

For R&D

If R&D occurs in tinidazole, it is likely to be:

• BE and lifecycle formulation (bioavailability optimization, improved stability, palatability, fixed-dose combinations).
• Line extensions that aim at manufacturing cost reduction or improved adherence rather than new mechanisms.

A credible differentiation strategy would target one of:

• Dosing convenience to improve adherence where clinicians prefer simplified regimens.
• Fixed-dose combinations (if locally permissible and commercially aligned).
• Improved formulation that reduces GI intolerance or improves tolerability in target populations.

For investment

Investment thesis generally rests on:

• Market access and distribution (tender wins, formulary inclusion).
• Manufacturing scale and supply reliability (unit cost advantage matters more than innovation).
• Geographic mix (emerging markets can support incremental volume while pricing remains constrained in mature markets).

Key Takeaways

• Tinidazole’s clinical activity is predominantly generic-support and maintenance-level rather than new, mechanism-changing late-stage development.
• The market is generic-led with structural price pressure, so revenue growth depends more on volume access and tender cycles than on clinical differentiation.
• The 2026–2035 outlook is stable-to-slow growth: moderate unit demand expansion with continued value suppression from pricing.
• Main projection risks are further price erosion, formulary displacement, and guideline-driven regimen shifts.

FAQs

1) Is tinidazole still under patent protection in major markets?

No; tinidazole is broadly available as generics across major markets, which drives pricing pressure and substitution.

2) What clinical trial types are most common for tinidazole today?

Most activity centers on bioequivalence, formulation support, and comparative studies in established indications rather than new therapeutic mechanisms.

3) Which indication group drives consistent demand?

Bacterial vaginosis and protozoal infections (amoebiasis, giardiasis) are the main ongoing demand drivers due to recurring incidence and guideline-based treatment patterns.

4) How does metronidazole affect tinidazole’s market?

Metronidazole is the primary therapeutic substitute. When payers and formularies prioritize lower cost or preferred regimens, tinidazole’s share can shift.

5) What would most change the market outlook?

A material expansion of approved indications, a new superior regimen adopted broadly, or a major regional supply disruption that affects tender availability.

---

References

[1] FDA. Tinidazole prescribing information / drug labeling (representative label sources for tinidazole oral formulations). U.S. Food and Drug Administration.
[2] EMA. EPAR and product information (where applicable for tinidazole-containing medicinal products). European Medicines Agency.
[3] WHO. Guidelines and antimicrobial use references relevant to anaerobic infections and protozoal infections. World Health Organization.
[4] PubMed. Tinidazole clinical trial records and bioequivalence studies (search results by tinidazole AND trial/bioequivalence). National Library of Medicine.
[5] Clinical reference sources for nitroimidazole use (anaerobic infections, giardiasis, amoebiasis, trichomoniasis, bacterial vaginosis). Medical literature and drug monographs used for standard dosing and indication positioning.